University of Colorado Cancer Center NCI-Designated Comprehensive Cancer Center | Strategic Alliance Partners

May 01, 2024

Experts on HER2-mutated NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

April 26, 2024

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

April 26, 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

April 24, 2024

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

April 24, 2024

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2-mutated non–small cell lung cancer.

April 19, 2024

In case you missed any, below is a recap of every episode of OncLive On Air that aired in March 2024.

September 27, 2023

S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.

September 20, 2023

D. Ross Camidge, MD, PhD, discusses the rationale for the ongoing phase 2 TRUST-II trial of taletrectinib in patients with non–small cell lung cancer harboring ROS1 mutations. 

August 24, 2023

In this episode of "How This Is Building Me," Drs Camidge and Vokes discuss the span of countries and institutions along Dr Vokes’ journey to MD Anderson Cancer Center, how Dr Vokes balances research and work in the clinic, and how the correct mentors can help shape career paths in oncology.

August 24, 2023

Breelyn Wilky, MD, discusses the rationale for investigating the addition of doxorubicin to zalifrelimab and balstilimab in patients with advanced/metastatic soft tissue sarcoma, expands on results from the phase 2 trial, and emphasizes the need for continued research for the potential role of immunotherapy in this patient population.

August 11, 2023

The combination of teclistamab and nirogacestat produced high and deep responses in patients with relapsed/refractory multiple myeloma.

July 24, 2023

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

July 17, 2023

Jeffrey V. Matous, MD, discusses upcoming and ongoing clinical trials in multiple myeloma being conducted at the Colorado Blood Cancer Institute.

July 14, 2023

Jeffrey V. Matous, MD, discusses the benefit derived from the phase 3 IKEMA trial in patients with relapsed/refractory multiple myeloma, highlighting the key factors to take into account when evaluating patients for relapsed/refractory disease within this treatment space.

July 13, 2023

Jeffrey V. Matous, MD, discusses potential strategies to overcome barriers to receiving CAR T-cell therapy for patients with multiple myeloma, and how the potential use of these agents in earlier lines could improve infusion wait times and rates of disease progression.

July 11, 2023

Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.

January 24, 2023

Jill Alldredge, MD, discusses the toxicities associated with PARP inhibition and the management of those adverse effects in patients with ovarian cancer.

January 18, 2023

Virginia F. Borges, MD, MMSc, and colleagues highlight updates across the breast cancer landscape, including key updates from the 2022 SABCS.

January 17, 2023

Saketh Guntupalli, MD, highlights data supporting PARP inhibitors as the standard-of-care frontline therapy, strategies for the management of PARP-related toxicities, and the importance of testing for HRD and BRCA status in patients with ovarian cancer.

January 17, 2023

Jill Alldredge, MD, discusses the management of symptoms in patients with ovarian cancer during treatment with a PARP inhibitor.